Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 3/20 | 0.44 |
| ▸ | MMP8 | P22894 | 2/20 | 0.44 |
| ▸ | LAP3 | P28838 | 3/20 | 0.41 |
| ▸ | ANPEP | P15144 | 2/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071586 | 0.78 | REN (0.42) | LAP3ANPEPRNPEPDNPEPCCR1 | |
| SCHEMBL4072541 | 0.76 | CTSD (0.43) | — | |
| SCHEMBL4069111 | 0.74 | C3AR1 (0.45) | CCR1 | |
| SCHEMBL4068864 | 0.74 | CCR1 (0.44) | MMP9MMP8PKMKMT2ACCR1 | |
| SCHEMBL4070249 | 0.73 | SLC1A3 (0.49) | MMP8LAP3ANPEPRNPEPDNPEP | |
| SCHEMBL4069924 | 0.73 | CCR1 (0.50) | ANPEPCCR1ERAP2ERAP1RECQL | |
| SCHEMBL7580246 | 0.73 | CCR1 (0.54) | LAP3ANPEPRNPEPDNPEPCCR1 | |
| SCHEMBL6832228 | 0.73 | CCR1 (0.54) | LAP3ANPEPRNPEPDNPEPCCR1 | |
| SCHEMBL4067803 | 0.72 | CCR1 (0.56) | ANPEPPKMKMT2ACCR1ERAP2 | |
| SCHEMBL2675795 | 0.72 | CCR1 (0.50) | LAP3ANPEPRNPEPDNPEPCCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966443-B1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER (US) | 2009-01-28 | — | — | EP | disclosed |
| US-20020198207-A1 | Novel Hexanoic acid derivatives | KATH JOHN CHARLES (US) | 2002-12-26 | — | — | US | disclosed |
| US-6403587-B1 | AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND | PFIZER INC. | 2002-06-11 | — | — | US | disclosed |
| EP-0966443-A1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER INC. (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998038167-A1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER INC. (US) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198207-A1 | Novel Hexanoic acid derivatives | HCAR3, HCAR1, FFAR1 | MMP9 4307/4885MMP8 3590/4885LAP3 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.